Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of blood cancer called Chronic Myelogenous Leukemia (CML), specifically in its early stage known as the chronic phase. The study is comparing two oral medications: Asciminib Hydrochloride and Nilotinib. Both medications are taken by mouth and are designed to help manage CML by targeting specific cancer cells. The purpose of the study is to evaluate how well patients tolerate these medications and how effective they are in treating CML.

Participants in the study will be randomly assigned to receive either Asciminib Hydrochloride or Nilotinib. The study will monitor how long patients can continue the treatment without stopping due to side effects. The trial will also look at how well the medications work in controlling the disease over time. Patients will be regularly assessed to track their response to the treatment and any side effects they may experience.

The study aims to provide valuable information about the safety and effectiveness of these treatments for people newly diagnosed with Chronic Myelogenous Leukemia in the chronic phase. The trial is expected to run for several years, allowing researchers to gather comprehensive data on the long-term outcomes of using these medications. Participants will receive regular check-ups and support throughout the study to ensure their well-being and to gather necessary information for the research.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying the diagnosis of chronic myeloid leukemia in the chronic phase and ensuring the presence of the Philadelphia chromosome.

    Laboratory tests are performed to check blood counts and organ function. These tests ensure that the body can handle the study medications.

  2. Step 2

    Randomization

    Participants are randomly assigned to receive either asciminib or nilotinib. This process is random to ensure unbiased results.

  3. Step 3

    Medication administration

    Participants take the assigned medication orally. The specific dosage and frequency are determined by the study protocol and are explained during the initial assessment.

    The duration of medication administration continues throughout the study unless discontinued due to adverse effects.

  4. Step 4

    Regular monitoring

    Regular visits are scheduled to monitor health and response to the medication. These visits include physical examinations, blood tests, and other necessary assessments.

    Monitoring helps track the effectiveness of the treatment and any side effects that may occur.

  5. Step 5

    Evaluation of treatment response

    The response to treatment is evaluated at various time points. This includes measuring the levels of the BCR::ABL1 gene, which is associated with the disease.

    The goal is to achieve a significant reduction in this gene's activity, indicating a positive response to treatment.

  6. Step 6

    Completion of study

    The study is estimated to conclude by March 2027. Participants will have a final assessment to evaluate overall health and treatment outcomes.

    The results contribute to understanding the tolerability and effectiveness of the medications for future treatment strategies.

Who can join the trial?

15 criteria

  • You must sign a form agreeing to participate in the study.
  • You must be a male or female who is 18 years of age or older.
  • You must have been diagnosed with **Chronic Myeloid Leukemia in Chronic Phase (CML-CP)** within the last 3 months.
  • Your diagnosis of CML-CP must be confirmed by specific tests, including the presence of the **Philadelphia (Ph) chromosome**. If the Ph chromosome is not visible, another test called **Fluorescence in situ Hybridization (FISH)** should confirm it.
  • Your blood and bone marrow tests must show:
    • Less than 15% of certain immature blood cells called **blasts**.
    • Less than 30% of blasts plus another type of immature cell called **promyelocytes**.
    • Less than 20% of a type of white blood cell called **basophils**.
    • A **platelet count** of at least 100,000 per cubic millimeter.
    • No signs of leukemia outside the bone marrow, except for possible enlargement of the liver or spleen.
    • You must have evidence of a specific genetic marker called **BCR::ABL1 transcript**, which can be measured by a test called **RQ-PCR**.
    • Your overall health must be good, as measured by a scale called the **Eastern Cooperative Oncology Group (ECOG) performance status**, with a score of 0 or 1.
    • Your organs must be functioning well, with specific blood test results showing:
      • Total **bilirubin** less than 3 times the normal limit, unless you have a condition called **Gilbert's syndrome**.
      • **Creatinine clearance** of at least 30 milliliters per minute, which measures kidney function.
      • **Serum lipase** levels within a safe range, which is an enzyme related to the pancreas.
      • Your blood levels of **potassium**, **calcium**, and **magnesium** must be within normal limits or corrected with supplements if needed. If you have mild to moderate kidney issues, these levels should still be normal or corrected.

Who cannot join the trial?

10 criteria

  • Patients who have been diagnosed with a type of blood cancer called Chronic Myeloid Leukemia in the Chronic Phase cannot participate if they have already received treatment for this condition.
  • Individuals who are not within the specified age range for the study cannot participate. The study is open to certain age groups, so those outside these groups are excluded.
  • Participants who are unable to follow the study procedures or take the study medication as required will not be able to join the trial.
  • People with other serious health conditions that might interfere with the study or put them at risk cannot participate.
  • Women who are pregnant or breastfeeding are not allowed to take part in the study.
  • Individuals who have a history of allergic reactions to the study medications or similar drugs are excluded.
  • Participants who are currently taking other medications that might interfere with the study treatment are not eligible.
  • Anyone who has participated in another clinical trial within a certain time frame before this study cannot join.
  • Individuals with a history of drug or alcohol abuse that might affect their ability to participate in the study are excluded.
  • Patients who have had a recent major surgery or are planning to have surgery during the study period cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Asciminib

    is a medication being studied for its ability to treat patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in the Chronic Phase. It works by specifically targeting and inhibiting a protein that is involved in the growth of cancer cells, which may help to slow down or stop the progression of the disease.

  • Nilotinib

    is another medication used in the study for treating the same type of leukemia. It is designed to block certain proteins that promote the growth of cancer cells, thereby helping to control the disease. The study aims to compare the tolerability and effectiveness of nilotinib with asciminib in patients.

What is already known about the treatment

  • Asciminib

    Asciminib is administered orally and is currently being studied in clinical trials for its effectiveness and safety in treating Chronic Myeloid Leukemia. It is a newer medication in the medical literature, primarily being evaluated for its tolerability compared to other treatments. Asciminib works by specifically targeting the BCR-ABL1 protein, which is responsible for the uncontrolled growth of cancer cells in this type of leukemia. It belongs to the class of drugs known as tyrosine kinase inhibitors, which help to block the signals that cause cancer cells to multiply.

  • Nilotinib

    Nilotinib is also taken orally and is an established medication used in the treatment of Chronic Myeloid Leukemia. It is well-documented in medical literature and is being compared to asciminib in clinical trials to evaluate its tolerability and effectiveness. Nilotinib functions by inhibiting the BCR-ABL1 protein, similar to asciminib, thereby preventing the growth and spread of cancer cells. It is classified as a tyrosine kinase inhibitor, a group of drugs that interfere with specific enzymes involved in cancer cell proliferation.

Investigated diseases

Chronic Myeloid Leukemia – Chronic Myeloid Leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the overproduction of immature white blood cells, known as myeloid cells. CML typically progresses through three phases: chronic, accelerated, and blast crisis. In the chronic phase, symptoms may be mild or absent, and the disease progresses slowly. As it advances to the accelerated phase, symptoms become more pronounced, and the number of abnormal cells increases. In the blast crisis phase, the disease behaves more like an acute leukemia, with rapid progression and severe symptoms.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-510947-71-00Protocol codeCABL001J12302Estimated enrolment576 patientsSponsorNovartis Pharma AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).